Methylenetetrahydrofolate reductase polymorphism and risk of colorectal adenomas

Cancer Lett. 2000 Apr 14;151(2):181-6. doi: 10.1016/s0304-3835(99)00412-7.


A homozygous mutation at bp 677 in the gene for the methylenetetrahydrofolate reductase (MTHFR) was previously shown to be associated with a decreased risk of colorectal cancer. We examined the relation between the MTHFR genetic polymorphism and risk of colorectal adenoma in Japanese men using 205 cases of colorectal adenomas and 220 controls of normal total colonoscopy. The homozygous mutation was not measurably associated with colorectal adenomas. The findings corroborate the lack of an association between the MTHFR genotype and colorectal adenomas, but do not deny the possibility that the genotype may be involved in the late stage of colorectal carcinogenesis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenoma / enzymology
  • Adenoma / etiology
  • Adenoma / genetics*
  • Adenoma / pathology
  • Alcohol Drinking
  • Colorectal Neoplasms / enzymology
  • Colorectal Neoplasms / etiology
  • Colorectal Neoplasms / genetics*
  • Colorectal Neoplasms / pathology
  • Genetic Predisposition to Disease / genetics*
  • Homozygote
  • Humans
  • Japan
  • Male
  • Methylenetetrahydrofolate Reductase (NADPH2)
  • Middle Aged
  • Mutation / genetics
  • Neoplasm Staging
  • Odds Ratio
  • Oxidoreductases Acting on CH-NH Group Donors / genetics*
  • Polymorphism, Genetic / genetics*


  • Oxidoreductases Acting on CH-NH Group Donors
  • Methylenetetrahydrofolate Reductase (NADPH2)